Ductal carcinoma in situ of the breast
DOI:
https://doi.org/10.18597/rcog.727Keywords:
Ductal carcinoma in situ, invasive cancer, mammogram, mastectomy, lumpectomy, breast conservation, chemopreventionAbstract
The ductal carcinoma in situ of the breast is a heterogeneous group of neoplasms, which has presented an increase in its incidence during the last decade; furthermore, it is a disease that is diagnosed in asymptomatic patients due to mammography screening.
There is not a single treatment for this pathology and in some cases is recommended radiotherapy use. It is known that chemoprevention has an important role in its management.
It is given some guidelines of management on the bases of the Van Nuys score.
Author Biography
Hernán Cortés Yepes
References
Bartow SA et al. Prevalence of benign, atypical and malignant breast lesions in populations at different risk for breast cancer. A forensic autopsy study. Cancer. 1987; 60: 2751-60.
Alpers CE, Wellings SR. The prevalence of carcinoma in situ in normal and cancer associated breasts. Hum Pathol. 1985; 16:796-807.
Ernster VL, Barclay J. Incidence and treatment for ductal carcinoma in situ of breast. JAMA 1997; 275: 913-918.
Fonseca R et al. Ductal carcinoma in situ of the breast. Ann Intern Med. 1997;127:1013-1022.
Simon MS et al. Recent trends in the incidence of in situ and invasive breast cancer. Cancer. 1993;71:769-74.
Liff JM et al. Does increase detection account for the rising incidence of breast cancer? Am J Public Health. 1991; 81:462-5.
Hwang ES, Esserman LJ. Management of ductal carcinoma in situ. In: Breast cancer management. Surg Clin N America.1999; 79 (5): 1007-1030.
Tavassoli FA. Ductal carcinoma in situ: Introduction of the concept of ductal intraephitelial neoplasia. Mod Pathol. 1998; 11:140-154.
Fisher ER, Costantino J, Fisher B. Pathologic findings from the NSABP B-17. Intraductal carcinoma. Cancer 1995; 75: 1310-1319.
Knutzen AM, Gisvold JJ. Likelihood of malignant disease for various categories of mammographically detected, non palpable breast lesions. Mayo Clin Proc. 1993; 68:454-60.
Page DL, Dupont WD. Intraductal carcinoma of the breast: follow-up after biopsy only. Cancer. 1982; 49:751-8.
Page DL, Dupont WD. Continued local recurrence of carcinoma 15-25 years after a diagnosis of low grade ductal carcinoma in situ of the breast treated only by biopsy. Cancer. 1995; 76:1197-200.
Holland R et al. Extent, distribution and mammographic/histological correlations of breast ductal carcinoma in situ. Lancet. 1990; 335:519-22.
Fisher B et al. Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer. N Engl J Med. 1993; 328:1581-6.
Silverstein MJ. Fortnightly review: Ductal carcinoma in situ of the breast. BMJ 1998; 317:734-739.
Fisher B et al. Tamoxifen in treatment of intraductal breast cancer. The NSABP B-24 protocol. Lancet. 1999; 353:1993-2000.
Silverstein MJ, Lagios MD, Craig PH et al. A prognostic index for ductal carcinoma in situ of the breast. Cancer. 1996; 77:2267-74.
How to Cite
Downloads
Downloads
Published
Issue
Section
| Article metrics | |
|---|---|
| Abstract views | |
| Galley vies | |
| PDF Views | |
| HTML views | |
| Other views | |
